Table 3.
(Final/Follow-up) Clinical Characteristics, N = 167 (single injection)
| N(%) or Median (25th–75th) | |||||
|---|---|---|---|---|---|
| All (N = 167) | CHOP (N = 72) | TSRH (N = 95) | P-value* | SMD | |
| Joint swelling | |||||
| > 1 (vs 0) | 48 (29%) | 15 (21%) | 33 (35%) | 0.0493 | 0.31 |
| Joint tenderness | |||||
| > 1 (vs 0) | 9 (5%) | 6 (8%) | 3 (3%) | 0.18 | 0.22 |
| Joint limited range of motion | |||||
| > 1 (vs 0) | 33 (20%) | 7 (10%) | 26 (27%) | 0.0046 | 0.47 |
| Arthritis reoccurrence – Yes | 55 (33%) | 19 (26%) | 36 (38%) | 0.14 | 0.25 |
| If yes, number of months until arthritis reoccurred | 10 (4–19) | 10 (4–19) | 10.5 (4–18) | 0.87 | 0.05 |
| CHAQ Score Follow-upa | 0.125 (0–0.50) | 0.125 (0–0.125) | 0.125 (0–0.50) | 0.26 | 0.20 |
| MD Global Score Follow-upb | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0.88 | 0.03 |
| Pain Assessment Follow-up (1–10) | 0 (0–3) | 0 (0–3.5) | 1(0–3) | 0.90 | 0.02 |
*Wilcoxon Rank-Sum tests or Chi-squared/Fisher’s Exact Tests between CHOP and TSRH sites, alpha = 0.05
aCHAQ missing, n = 34
bMD Global missing, n = 30
cPain assessment missing, n = 36
SMD: standardized mean difference. SMD > 0.25 (25%) indicates an imbalance between groups, P < 0.05 is considered statistically significant (shown in bold)